Nyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%

MT Newswires Live

2024/10/16

Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.

The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.

The drug development firm anticipates the phase one trial to start later in the year, as per the filing.

The company climbed past 31% in recent Wednesday trade.

Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2475446628"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2475446628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2475446628?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-16 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475446628","market":"sh","top_or_hot":-1,"title":"Nyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%","media":"MT Newswires Live","content":"<html><body><p> Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.</p><p>The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.</p><p>The drug development firm anticipates the phase one trial to start later in the year, as per the filing.</p><p>The company climbed past 31% in recent Wednesday trade.</p><p>Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyrada Completes Preclinical Studies Ahead of Stroke Therapy's Phase One Trial; Shares Climb 31%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-16 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.</p><p>The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.</p><p>The drug development firm anticipates the phase one trial to start later in the year, as per the filing.</p><p>The company climbed past 31% in recent Wednesday trade.</p><p>Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475446628","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475446628","pubTimestamp":1729042460,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nyrada  completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.The drug development firm anticipates the phase one trial to start later in the year, as per the filing.The company climbed past 31% in recent Wednesday trade.Price : $0.13, Change: $+0.03, Percent Change: +31.31%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","NYR.AU":"NYRADA INC-CDI","BK4125":"广播"},"translate_title":"Nyrada在中风治疗一期试验之前完成临床前研究；股价上涨31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"NYR.AU":0.9},"content_text":"Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.The drug development firm anticipates the phase one trial to start later in the year, as per the filing.The company climbed past 31% in recent Wednesday trade.Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}